Literature DB >> 9604935

Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation.

A V Khokhlatchev1, B Canagarajah, J Wilsbacher, M Robinson, M Atkinson, E Goldsmith, M H Cobb.   

Abstract

The MAP kinase ERK2 is widely involved in eukaryotic signal transduction. Upon activation it translocates to the nucleus of the stimulated cell, where it phosphorylates nuclear targets. We find that nuclear accumulation of microinjected ERK2 depends on its phosphorylation state rather than on its activity or on upstream components of its signaling pathway. Phosphorylated ERK2 forms dimers with phosphorylated and unphosphorylated ERK2 partners. Disruption of dimerization by mutagenesis of ERK2 reduces its ability to accumulate in the nucleus, suggesting that dimerization is essential for its normal ligand-dependent relocalization. The crystal structure of phosphorylated ERK2 reveals the basis for dimerization. Other MAP kinase family members also form dimers. The generality of this behavior suggests that dimerization is part of the mechanism of action of the MAP kinase family.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9604935     DOI: 10.1016/s0092-8674(00)81189-7

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  203 in total

1.  Changes in protein conformational mobility upon activation of extracellular regulated protein kinase-2 as detected by hydrogen exchange.

Authors:  A N Hoofnagle; K A Resing; E J Goldsmith; N G Ahn
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

2.  Biochemical and biological functions of the N-terminal, noncatalytic domain of extracellular signal-regulated kinase 2.

Authors:  S T Eblen; A D Catling; M C Assanah; M J Weber
Journal:  Mol Cell Biol       Date:  2001-01       Impact factor: 4.272

3.  A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking.

Authors:  J M Stommel; N D Marchenko; G S Jimenez; U M Moll; T J Hope; G M Wahl
Journal:  EMBO J       Date:  1999-03-15       Impact factor: 11.598

Review 4.  Mitogen-activated protein kinases: specific messages from ubiquitous messengers.

Authors:  H J Schaeffer; M J Weber
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

5.  Characterization of Fus3 localization: active Fus3 localizes in complexes of varying size and specific activity.

Authors:  K Y Choi; J E Kranz; S K Mahanty; K S Park; E A Elion
Journal:  Mol Biol Cell       Date:  1999-05       Impact factor: 4.138

6.  ERK2 enters the nucleus by a carrier-independent mechanism.

Authors:  Angelique W Whitehurst; Julie L Wilsbacher; Youngjai You; Kate Luby-Phelps; Mary Shannon Moore; Melanie H Cobb
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

7.  Transcriptional repressor ERF is a Ras/mitogen-activated protein kinase target that regulates cellular proliferation.

Authors:  L Le Gallic; D Sgouras; G Beal; G Mavrothalassitis
Journal:  Mol Cell Biol       Date:  1999-06       Impact factor: 4.272

8.  Disease resistance and abiotic stress tolerance in rice are inversely modulated by an abscisic acid-inducible mitogen-activated protein kinase.

Authors:  Lizhong Xiong; Yinong Yang
Journal:  Plant Cell       Date:  2003-03       Impact factor: 11.277

Review 9.  GnRH signaling, the gonadotrope and endocrine control of fertility.

Authors:  Stuart P Bliss; Amy M Navratil; Jianjun Xie; Mark S Roberson
Journal:  Front Neuroendocrinol       Date:  2010-05-06       Impact factor: 8.606

10.  Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.

Authors:  Tanios Bekaii-Saab; Mitch A Phelps; Xiaobai Li; Motoyasu Saji; Laura Goff; John Sae Wook Kauh; Bert H O'Neil; Stephanie Balsom; Catherine Balint; Ryan Liersemann; Vasily V Vasko; Mark Bloomston; William Marsh; L Austin Doyle; Gilian Ellison; Michael Grever; Matthew D Ringel; Miguel A Villalona-Calero
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.